HCM Prevalence, Pathophysiology, and Natural Course with and without Adequate Medical Treatment

Dec 21, 2022 | HCM

2a) This program is intended for #healthcare providers and is supported by an educational grant from Bristol-Myers Squibb. Statement of accreditation and faculty disclosures at https://t.co/gvXca4GHMU. FOLLOW US for the most timely expert education in #cardiometabolic...

Evaluating Post-Intervention Treatment Options for PAD

Jun 28, 2022 | PAD

2) The @cardiomet_ce program is supported by educational grants from AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company, Bristol Myers Squibb & its Alliance partner Pfizer Inc, Chiesi, & Esperion. This program is intended for...

Preventing Hyperkalemia from Derailing Evidence-Based CV Care

Jun 22, 2022 | HYPERKALEMIA

2) This #accredited #tweetorial series on #kidneydisease #hyperkalemia is supported by an independent educational grant from AstraZeneca and is intended for healthcare providers. Accreditation statement & faculty disclosures are at https://t.co/gvXca4G9Xm.—...

Optimizing Medical Therapy for Patients with HFrEF

Jun 15, 2022 | CARDIORENAL

1b) @ValleAlfonso is Jefe Servicio Cardiologia, Área del Corazón, Marina Salud. Denia Servicio de Cardiología Hospital La Salud, Valencia. He is a dedicated #cardiology researcher & #educator & appreciates the value of #SoMe education! #cardiotwitter...

Challenging Case Presentations for the Management of Patients with Cardiometabolic Disease

Jun 7, 2022 | CARDIORENAL

2) She is a member of UKCPA Diabetes & Endocrinology committee @UKCPADiabetes & works across #diabetes, #endocrinology, & emergency/acute care in Secondary Care. She is currently involved in development of regional guidelines & education to support...